Clinical Trial Update: Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT) [Phase 4]

View source ↗

Summary

Phase 4 trial comparing ranibizumab monotherapy versus ranibizumab combined with verteporfin photodynamic therapy for symptomatic macular polypoidal choroidal v…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Polypoidal Choroidal Vasculopathy

Drugs mentioned

• Ranibizumab (ranibizumab)
• Verteporfin (verteporfin)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy | Phase 4 | Status: COMPLETED | Results posted: 2019-06-07